BICO Group AB (publ) (BCCOY) Research

BICO Group AB (publ), originally founded in 2016 as Cellink AB (publ) in Gothenburg, Sweden, and subsequently renamed in August 2021, functions as a bio-convergence leader. The company extends its operations internationally, with a presence spanning North America, Europe, and Asia. Its business is structured into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment provides sophisticated scientific equipment, including 3D bioprinters, hybrid microscopes, single-cell dispensing devices, and liquid handling instruments. This division also supplies critical consumables such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues, particularly those utilized in regulatory testing. Furthermore, it offers specialized services in areas like 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology, primarily serving pharmaceutical and biotechnology enterprises. In contrast, the Bioautomation segment delivers precision dispensing and biosensor technologies to industrial customers. It also provides advanced robotics and diagnostics automation solutions tailored for the medical and diagnostic sectors. Beyond these, this segment develops comprehensive solutions encompassing core industrial ecosystems, tissue engineering, multi-omics, cell line development, and diagnostics. Its main clientele comprises the medical, pharmaceutical, and cosmetic industries.

Open BICO Group AB (publ) (BCCOY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.